XML 45 R31.htm IDEA: XBRL DOCUMENT v3.22.4
Note 9 - Stock-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2022
Notes Tables  
Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]
   

Shares Available for Grant

   

Number of Shares Outstanding

   

Weighted-Average Exercise Price

 

Balance as of December 31, 2020

    380       5,327     $ 1.14  

Authorized

    816       -       -  

Options Granted

    (1,141 )     1,141       5.60  

RSAs Granted

    (154 )     -       -  

Exercised

    -       (2,498 )     1.39  

Forfeited/expired

    241       (207 )     1.84  

Balance as of December 31, 2021

    142       3,763     $ 2.29  

Authorized

    1,338       -       -  

Options Granted

    (1,307 )     1,307       10.97  

RSAs Granted

    (89 )     -       -  

Exercised

    -       (295 )     0.93  

Forfeited/expired

    81       (81 )     11.63  

Balance as of December 31, 2022

    165       4,694     $ 4.63  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]
   

Number of Shares

   

Weighted Average Exercise Price

   

Remaining Contractual Term (In Years)

   

Aggregate Intrinsic Value1

 

2022

                               

Vested and Exercisable

    3,170     $ 2.46       6.98     $ 7,419  

Unvested

    1,524       9.13       8.81       647  

Total

    4,694     $ 4.63       7.58     $ 8,066  
                                 

2021

                               

Vested and Exercisable

    2,346     $ 1.32       7.68     $ 25,771  

Unvested

    1,417       3.89       8.64       12,961  

Total

    3,763     $ 2.29       8.04     $ 38,732  
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Description

 

For the year ended December 31,

 
   

2022

   

2021

 

Dividend-yield

    0 %     0 %

Risk-free interest rate

    2.03 %     0.83 %

Expected volatility

    117.21 %     100.47 %

Expected life (years)

    7.00       6.59  

Market value per share on grant date

  $ 10.97     $ 5.60  

Fair value per share on grant date

  $ 9.71     $ 4.68